Logo image of AMLX

AMYLYX PHARMACEUTICALS INC (AMLX) Stock Fundamental Analysis

NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD

5.145  +0.24 (+5%)

Fundamental Rating

4

Overall AMLX gets a fundamental rating of 4 out of 10. We evaluated AMLX against 198 industry peers in the Pharmaceuticals industry. While AMLX has a great health rating, there are worries on its profitability. AMLX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AMLX had negative earnings in the past year.
In the past year AMLX has reported a negative cash flow from operations.
AMLX had negative earnings in 4 of the past 5 years.
In the past 5 years AMLX reported 4 times negative operating cash flow.
AMLX Yearly Net Income VS EBIT VS OCF VS FCFAMLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

AMLX's Return On Assets of -155.83% is on the low side compared to the rest of the industry. AMLX is outperformed by 82.32% of its industry peers.
The Return On Equity of AMLX (-183.14%) is worse than 66.67% of its industry peers.
Industry RankSector Rank
ROA -155.83%
ROE -183.14%
ROIC N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
AMLX Yearly ROA, ROE, ROICAMLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

AMLX's Gross Margin of 63.50% is fine compared to the rest of the industry. AMLX outperforms 70.20% of its industry peers.
AMLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMLX Yearly Profit, Operating, Gross MarginsAMLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

AMLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMLX has been increased compared to 1 year ago.
Compared to 5 years ago, AMLX has more shares outstanding
AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMLX Yearly Shares OutstandingAMLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
AMLX Yearly Total Debt VS Total AssetsAMLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 3.31 indicates that AMLX is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.31, AMLX is doing good in the industry, outperforming 77.78% of the companies in the same industry.
AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.31
ROIC/WACCN/A
WACC9.57%
AMLX Yearly LT Debt VS Equity VS FCFAMLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.67 indicates that AMLX has no problem at all paying its short term obligations.
The Current ratio of AMLX (6.67) is better than 77.27% of its industry peers.
A Quick Ratio of 6.67 indicates that AMLX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.67, AMLX is doing good in the industry, outperforming 77.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.67
Quick Ratio 6.67
AMLX Yearly Current Assets VS Current LiabilitesAMLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AMLX have decreased strongly by -452.86% in the last year.
Looking at the last year, AMLX shows a very negative growth in Revenue. The Revenue has decreased by -76.88% in the last year.
Measured over the past years, AMLX shows a very strong growth in Revenue. The Revenue has been growing by 127.75% on average per year.
EPS 1Y (TTM)-452.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-885.71%
Revenue 1Y (TTM)-76.88%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%-100.61%

3.2 Future

The Earnings Per Share is expected to grow by 11.90% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.65% on average over the next years. This is quite good.
EPS Next Y22.28%
EPS Next 2Y17.08%
EPS Next 3Y9.51%
EPS Next 5Y11.9%
Revenue Next Year-100%
Revenue Next 2Y-96.17%
Revenue Next 3Y-50.48%
Revenue Next 5Y11.65%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AMLX Yearly Revenue VS EstimatesAMLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
AMLX Yearly EPS VS EstimatesAMLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMLX. In the last year negative earnings were reported.
Also next year AMLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMLX Price Earnings VS Forward Price EarningsAMLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMLX Per share dataAMLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.08%
EPS Next 3Y9.51%

More info and screens

0

5. Dividend

5.1 Amount

AMLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMYLYX PHARMACEUTICALS INC

NASDAQ:AMLX (4/30/2025, 3:47:06 PM)

5.145

+0.24 (+5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04 2025-03-04/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners62.84%
Inst Owner Change0.03%
Ins Owners8.26%
Ins Owner Change2.3%
Market Cap455.85M
Analysts80
Price Target10.2 (98.25%)
Short Float %6.06%
Short Ratio5.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.72%
Min EPS beat(2)-47.75%
Max EPS beat(2)-3.7%
EPS beat(4)1
Avg EPS beat(4)-477.57%
Min EPS beat(4)-1860.78%
Max EPS beat(4)1.96%
EPS beat(8)3
Avg EPS beat(8)-212.57%
EPS beat(12)5
Avg EPS beat(12)-142.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)2.5%
EPS NQ rev (3m)23.23%
EPS NY rev (1m)6.21%
EPS NY rev (3m)-7.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.18
P/FCF N/A
P/OCF N/A
P/B 2.77
P/tB 2.77
EV/EBITDA N/A
EPS(TTM)-2.47
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-1.89
OCFYN/A
SpS0.99
BVpS1.86
TBVpS1.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.83%
ROE -183.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.5%
FCFM N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4022.12%
Cap/Sales 41.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.67
Quick Ratio 6.67
Altman-Z 3.31
F-Score3
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)1551.62%
Cap/Depr(5y)4086.74%
Cap/Sales(3y)17.77%
Cap/Sales(5y)40.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-452.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-885.71%
EPS Next Y22.28%
EPS Next 2Y17.08%
EPS Next 3Y9.51%
EPS Next 5Y11.9%
Revenue 1Y (TTM)-76.88%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%-100.61%
Revenue Next Year-100%
Revenue Next 2Y-96.17%
Revenue Next 3Y-50.48%
Revenue Next 5Y11.65%
EBIT growth 1Y-520.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2010.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1506.55%
OCF growth 3YN/A
OCF growth 5YN/A